SDF-1產(chǎn)品信息
英文名稱:C-X-C motif chemokine ligand 12
中文名稱:C-X-C基序趨化因子配體12
靶點(diǎn)別稱:SDF-1,CXCL12,hSDF-1,IRH,hIRH,PBSF,SDF1,SDF1A,SDF1B
物種:Human
屬性:Protein
標(biāo)記:Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
SDF-1用戶評(píng)價(jià)
SDF-1分子背景
通過(guò)LYN激酶作為單核細(xì)胞遷移的正調(diào)節(jié)因子和單核細(xì)胞粘附的負(fù)調(diào)節(jié)因子。通過(guò)其受體CXCR4和ACKR3刺激單核細(xì)胞和T淋巴細(xì)胞的遷移,并減少單核細(xì)胞對(duì)ICAM-1(β-2整合素的配體)表面的粘附。SDF1A/CXCR4信號(hào)軸通過(guò)LYN激酶抑制β-2整合素LFA-1介導(dǎo)的單核細(xì)胞與ICAM-1的粘附。抑制由T細(xì)胞系適應(yīng)的HIV-1介導(dǎo)的CXCR4感染。在心肌梗死后起保護(hù)作用。誘導(dǎo)各種細(xì)胞中表達(dá)的ACKR3的下調(diào)和內(nèi)化。在胚胎發(fā)育過(guò)程中具有幾個(gè)關(guān)鍵功能;B細(xì)胞淋巴細(xì)胞生成、骨髓中的骨髓生成和心室間隔形成所必需的。在IL7存在的情況下刺激骨髓源性B細(xì)胞祖細(xì)胞的增殖以及基質(zhì)細(xì)胞依賴性前B細(xì)胞的生長(zhǎng)。
關(guān)鍵字: SDF-1;SDF-1蛋白;CXCL12;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。